Symmetric dimethylarginine is a marker of detrimental outcome in the acute phase after ischaemic stroke: role of renal function.
Standard
Symmetric dimethylarginine is a marker of detrimental outcome in the acute phase after ischaemic stroke: role of renal function. / Lüneburg, Nicole; von Holten, Rouven-Alexander; Töpper, Rudolf F; Schwedhelm, Edzard; Maas, Renke; Böger, Rainer.
in: CLIN SCI, Jahrgang 122, Nr. 3, 3, 2012, S. 105-111.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Symmetric dimethylarginine is a marker of detrimental outcome in the acute phase after ischaemic stroke: role of renal function.
AU - Lüneburg, Nicole
AU - von Holten, Rouven-Alexander
AU - Töpper, Rudolf F
AU - Schwedhelm, Edzard
AU - Maas, Renke
AU - Böger, Rainer
PY - 2012
Y1 - 2012
N2 - Methylarginines have been shown to interfere with NO (nitric oxide) formation by inhibiting NOS (NO synthase)-ADMA (asymmetric dimethylarginine) and cellular L-arginine uptake into the cell [ADMA and SDMA (symmetric dimethylarginine)]. In a recent study, elevation of SDMA was related to long-term mortality in patients recruited 30 days after a stroke event. In the present study, we aimed at investigating the association of SDMA and adverse clinical outcome in the early phase (first 30 days) after acute ischaemic stroke. A total of 137 patients were recruited immediately upon admission to the emergency unit with an acute ischaemic stroke. Plasma levels of methylarginines were determined by a validated LC-MS/MS (liquid chromatography-tandem MS) method. Patients were prospectively followed for 30 days. A total of 25 patients (18.2%) experienced the primary composite endpoint [death, recurrent stroke, MI (myocardial infarction) and rehospitalization]. SDMA plasma levels were significantly higher in stroke patients compared with patients without event (0.89 ± 0.80 compared with 0.51 ± 0.24 ?mol/l; P
AB - Methylarginines have been shown to interfere with NO (nitric oxide) formation by inhibiting NOS (NO synthase)-ADMA (asymmetric dimethylarginine) and cellular L-arginine uptake into the cell [ADMA and SDMA (symmetric dimethylarginine)]. In a recent study, elevation of SDMA was related to long-term mortality in patients recruited 30 days after a stroke event. In the present study, we aimed at investigating the association of SDMA and adverse clinical outcome in the early phase (first 30 days) after acute ischaemic stroke. A total of 137 patients were recruited immediately upon admission to the emergency unit with an acute ischaemic stroke. Plasma levels of methylarginines were determined by a validated LC-MS/MS (liquid chromatography-tandem MS) method. Patients were prospectively followed for 30 days. A total of 25 patients (18.2%) experienced the primary composite endpoint [death, recurrent stroke, MI (myocardial infarction) and rehospitalization]. SDMA plasma levels were significantly higher in stroke patients compared with patients without event (0.89 ± 0.80 compared with 0.51 ± 0.24 ?mol/l; P
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Multivariate Analysis
KW - Prognosis
KW - Follow-Up Studies
KW - Time Factors
KW - Proportional Hazards Models
KW - Kaplan-Meier Estimate
KW - Chromatography, Liquid
KW - Tandem Mass Spectrometry
KW - Brain Ischemia/complications
KW - Arginine/analogs & derivatives/blood
KW - Biological Markers/blood
KW - Kidney/physiopathology
KW - Outcome Assessment (Health Care)/statistics & numerical data
KW - Stroke/blood/diagnosis/etiology
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Multivariate Analysis
KW - Prognosis
KW - Follow-Up Studies
KW - Time Factors
KW - Proportional Hazards Models
KW - Kaplan-Meier Estimate
KW - Chromatography, Liquid
KW - Tandem Mass Spectrometry
KW - Brain Ischemia/complications
KW - Arginine/analogs & derivatives/blood
KW - Biological Markers/blood
KW - Kidney/physiopathology
KW - Outcome Assessment (Health Care)/statistics & numerical data
KW - Stroke/blood/diagnosis/etiology
M3 - SCORING: Journal article
VL - 122
SP - 105
EP - 111
JO - CLIN SCI
JF - CLIN SCI
SN - 0143-5221
IS - 3
M1 - 3
ER -
